| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
110.01(B) |
| Last
Volume: |
507,716 |
Avg
Vol: |
759,306 |
| 52
Week Range: |
$692.45 - $1071.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
192,108 |
259,662 |
311,759 |
469,743 |
| Total Sell Value |
$188,697,290 |
$251,749,241 |
$294,950,701 |
$405,465,351 |
| Total People Sold |
7 |
14 |
16 |
18 |
| Total Sell Transactions |
18 |
45 |
67 |
128 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-26 |
4 |
AS |
$452.04 |
$91,242 |
D/D |
(200) |
24,973 |
|
51% |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-02-26 |
4 |
S |
$451.61 |
$7,152,016 |
D/D |
(15,642) |
28,251 |
|
-51% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-25 |
4 |
AS |
$438.00 |
$96,088 |
D/D |
(214) |
25,173 |
|
47% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-25 |
4 |
D |
$447.30 |
$357,840 |
D/D |
(800) |
25,387 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-25 |
4 |
OE |
$272.70 |
$272,700 |
D/D |
1,000 |
26,187 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-02-25 |
4 |
D |
$447.30 |
$7,645,699 |
D/D |
(17,093) |
43,893 |
|
- |
|
| Van Plew Daniel P |
EVP & General Mgr Industrial O |
• – – |
2020-02-25 |
4 |
OE |
$30.63 |
$1,002,673 |
D/D |
32,735 |
60,986 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-24 |
4 |
D |
$406.59 |
$319,580 |
D/D |
(786) |
25,187 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-24 |
4 |
OE |
$272.70 |
$272,700 |
D/D |
1,000 |
25,973 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2020-02-24 |
4 |
AS |
$420.17 |
$49,631,741 |
D/D |
(118,123) |
517,799 |
|
46% |
|
| Brown Michael S |
Director |
– • – |
2020-02-24 |
4 |
AS |
$419.00 |
$838,001 |
D/D |
(2,000) |
643 |
|
46% |
|
| Brown Michael S |
Director |
– • – |
2020-02-24 |
4 |
OE |
$273.67 |
$547,340 |
D/D |
2,000 |
2,643 |
|
- |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2020-02-13 |
4 |
S |
$398.71 |
$5,711,711 |
D/D |
(14,279) |
1,830 |
|
-49% |
|
| Tessier-Lavigne Marc |
Director |
– • – |
2020-02-13 |
4 |
OE |
$50.91 |
$757,944 |
D/D |
14,279 |
11,109 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-02-13 |
4 |
AS |
$399.80 |
$4,117,958 |
D/D |
(10,278) |
11,380 |
|
49% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-13 |
4 |
AS |
$398.63 |
$42,806 |
D/D |
(107) |
24,973 |
|
49% |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-02-12 |
4 |
D |
$402.34 |
$5,923,249 |
D/D |
(14,722) |
21,658 |
|
- |
|
| Stahl Neil |
EVP Research and Development |
• – – |
2020-02-12 |
4 |
OE |
$52.03 |
$1,300,750 |
D/D |
25,000 |
36,380 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-12 |
4 |
D |
$402.34 |
$158,120 |
D/D |
(393) |
25,080 |
|
- |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2020-02-12 |
4 |
OE |
$272.70 |
$136,350 |
D/D |
500 |
25,473 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2020-02-07 |
4 |
S |
$382.83 |
$382,830 |
D/D |
(1,000) |
9,643 |
|
-56% |
|
| Murphy Andrew J |
EVP Research |
• – – |
2020-01-27 |
4 |
AS |
$336.78 |
$2,727,279 |
D/D |
(8,000) |
49,951 |
|
67% |
|
| Fenimore Christopher R. |
VP Controller |
• – – |
2020-01-24 |
4 |
OE |
$30.63 |
$15,315 |
D/D |
500 |
13,097 |
|
- |
|
| Vagelos P Roy |
Chairman of the Board |
• • – |
2020-01-03 |
4 |
GD |
$0.00 |
$0 |
I/I |
564 |
144,333 |
|
- |
|
| Ryan Arthur F |
Director |
– • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
29,143 |
|
- |
|
2430 Records found
|
|
Page 34 of 98 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
18.30 (1.71%) 
